Auto-brewery syndrome (ABS) is a rarely diagnosed disorder in which gut microorganisms produce enough ethanol from dietary carbohydrate to raise systemic blood ethanol and cause intoxication without exogenous alcohol consumption. The best current cohort evidence implicates flare-associated bacterial dysbiosis, particularly ethanol-producing Escherichia coli and Klebsiella pneumoniae and enriched fermentation pathways. Fungal overgrowth has been demonstrated in selected cases but was not a cohort-wide signature in the largest microbiome study. Diagnosis therefore requires a supervised rise in blood ethanol, usually after an oral glucose challenge, rather than symptoms or a positive microbial culture alone.
Ask a research question about Auto-Brewery Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Auto-Brewery Syndrome:
name: Auto-Brewery Syndrome
creation_date: '2026-01-17T04:34:30Z'
category: Complex
description: >-
Auto-brewery syndrome (ABS) is a rarely diagnosed disorder in which gut
microorganisms produce enough ethanol from dietary carbohydrate to raise
systemic blood ethanol and cause intoxication without exogenous alcohol
consumption. The best current cohort evidence implicates flare-associated
bacterial dysbiosis, particularly ethanol-producing Escherichia coli and
Klebsiella pneumoniae and enriched fermentation pathways. Fungal overgrowth
has been demonstrated in selected cases but was not a cohort-wide signature
in the largest microbiome study. Diagnosis therefore requires a supervised
rise in blood ethanol, usually after an oral glucose challenge, rather than
symptoms or a positive microbial culture alone.
synonyms:
- Gut fermentation syndrome
- Endogenous alcohol fermentation syndrome
- Endogenous ethanol fermentation syndrome
disease_term:
preferred_term: auto-brewery syndrome
term:
id: MONDO:0971031
label: auto-brewery syndrome
parents:
- Gastrointestinal disorders
- Metabolic disorders
epidemiology:
- name: Published Case Burden and Unknown Population Prevalence
description: >-
Population prevalence is unknown. The 2021 systematic review identified 17
case reports comprising 20 patients, underscoring both the rarity of the
published diagnosis and the absence of population-level prevalence data.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In total, 17 case reports were included, consisting of 20 patients
diagnosed with GFS.
explanation: >-
The systematic review quantifies the small published case literature; it
does not establish population prevalence.
progression:
- phase: Carbohydrate-triggered intoxication flares and remission
notes: >-
ABS commonly follows an episodic course. Carbohydrate exposure can precede
a rise in ethanol, while microbiome composition, stool ethanol-production
capacity, and symptoms differ between flare and remission samples. Duration
and recurrence vary, and standardized longitudinal natural-history data are
not yet available.
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Faecal samples from individuals with ABS during a flare produced more
ethanol in vitro, which could be reduced by antibiotic treatment.
explanation: >-
The observational cohort directly compared symptomatic flares with other
clinical states and found increased microbial ethanol-production capacity.
clinical_burden:
burden_level: HIGH
rationale: >-
In clinically manifest ABS, unpredictable intoxication can impair cognition,
coordination, relationships, employment, and driving, and can lead to falls,
injury, or legal consequences. Burden varies among patients, but the potential
severity and difficulty obtaining a credible diagnosis justify a high burden
classification for symptomatic disease.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These symptoms can have severe impact on patients' wellbeing and can have
social and legal consequences.
explanation: >-
The systematic review directly documents major wellbeing, social, and legal
effects across the case literature.
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most significant event caused by one of his inebriations was a fall
that caused intracranial bleeding
explanation: >-
A confirmed case demonstrates that an intoxication flare can cause serious
physical injury.
pathophysiology:
- name: Flare-Associated Bacterial Gut Dysbiosis
biological_scale: TISSUE
mechanism_confidence: ESTABLISHED
description: >-
During documented ABS flares, the gut microbiome shows lower diversity and
enrichment of Proteobacteria and Enterobacteriaceae, including Escherichia
coli and Klebsiella pneumoniae. Stool from flares produces more ethanol in
culture than stool from remission or unaffected household-partner samples.
These findings support bacterial dysbiosis as the dominant mechanism in the
largest available cohort, without implying that one organism explains every
case.
locations:
- preferred_term: intestine
term:
id: UBERON:0000160
label: intestine
biological_processes:
- preferred_term: fermentation
term:
id: GO:0006113
label: fermentation
modifier: INCREASED
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Gut microbiome analysis using metagenomics revealed an enrichment of
Proteobacteria, including Escherichia coli and Klebsiella pneumoniae.
explanation: >-
The 22-patient cohort identifies a flare-associated bacterial taxonomic
signature in clinically documented ABS.
- reference: PMID:37060744
reference_title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The abundance of the genus Klebsiella in Enterobacteriaceae was strongly
associated with fluctuations of patient's blood alcohol concentration.
explanation: >-
An independent case-control study links Klebsiella abundance with the
clinical blood-ethanol phenotype.
downstream:
- target: Excess Gut Microbial Ethanol Production
causal_link_type: DIRECT
description: >-
Enriched ethanol-producing bacteria and fermentation pathways directly
increase ethanol generation from carbohydrate in the intestinal lumen.
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Faecal samples from individuals with ABS during a flare produced more
ethanol in vitro, which could be reduced by antibiotic treatment.
explanation: >-
Flare samples directly produced excess ethanol ex vivo, and antibacterial
exposure reduced that production.
- name: Fungal Overgrowth in a Subset of Cases
biological_scale: TISSUE
mechanism_confidence: PROVISIONAL
description: >-
Candida and Saccharomyces species have been cultured from the gastrointestinal
tract in selected ABS cases, and sensitivity-guided antifungal treatment has
been followed by a negative rechallenge. This mechanism remains provisional
at the disease-wide level: the largest cohort found no significant fungal
compositional difference, although prior antifungal exposure limited that
analysis.
locations:
- preferred_term: intestine
term:
id: UBERON:0000160
label: intestine
biological_processes:
- preferred_term: pyruvate fermentation to ethanol
term:
id: GO:0019655
label: pyruvate fermentation to ethanol
modifier: INCREASED
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The patient in this case report had fungal yeast forms in the upper small
bowel and cecum, which likely fermented carbohydrates to alcohol.
explanation: >-
A confirmed case directly localized fungal yeast forms to gastrointestinal
sites and linked them to carbohydrate fermentation.
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The species that caused the GFS included Klebsiella pneumoniae, Candida
albicans, C. glabrata, Saccharomyces cerevisiae, C. intermedia, C.
parapsilosis, and C. kefyr.
explanation: >-
The systematic review documents several Candida and Saccharomyces species
in published cases.
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Analysis of the gut fungal microbiome by ITS2 sequencing demonstrated no
significant differences in fungal composition between patients with ABS
and household partners
explanation: >-
The largest cohort did not find a disease-wide fungal compositional signal,
limiting generalization from individual culture-confirmed cases.
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
However, increased antifungal use after ABS diagnosis (Table 2) may have
suppressed intestinal fungal growth, so we cannot rule out a potential role
for fungi in certain patients.
explanation: >-
Prior antifungal exposure prevents interpreting the negative cohort-wide
fungal result as exclusion of fungal ABS in selected patients.
downstream:
- target: Excess Gut Microbial Ethanol Production
causal_link_type: DIRECT
description: >-
In fungal-associated cases, yeast fermentation directly produces ethanol
from ingested carbohydrate.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatment with antifungal agents allowed subsequent ingestion of
carbohydrates without symptoms.
explanation: >-
Resolution after targeted antifungal treatment and subsequent carbohydrate
ingestion supports a causal fungal fermentation mechanism in this case.
- name: Excess Gut Microbial Ethanol Production
biological_scale: MOLECULAR
mechanism_confidence: ESTABLISHED
description: >-
Dysregulated intestinal microorganisms convert dietary carbohydrate to
ethanol. In the 2026 cohort, mixed-acid and heterolactic fermentation and
ethanolamine-utilization pathways were enriched, and stool ethanol production
was greatest during clinical flares.
locations:
- preferred_term: intestine
term:
id: UBERON:0000160
label: intestine
biological_processes:
- preferred_term: fermentation
term:
id: GO:0006113
label: fermentation
modifier: INCREASED
- preferred_term: pyruvate fermentation to ethanol
term:
id: GO:0019655
label: pyruvate fermentation to ethanol
modifier: INCREASED
chemical_entities:
- preferred_term: ethanol
term:
id: CHEBI:16236
label: ethanol
modifier: INCREASED
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Genes in metabolic pathways associated with ethanol production were
enriched, including the mixed-acid fermentation pathway, heterolactic
fermentation pathway and ethanolamine utilization pathway.
explanation: >-
Metagenomic pathway enrichment provides molecular support for excess
microbial ethanol production.
downstream:
- target: Systemic Ethanol Exposure
causal_link_type: DIRECT
description: >-
Microbially produced luminal ethanol is absorbed from the gastrointestinal
tract into the systemic circulation.
evidence:
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients exhibit symptoms of intoxication due to systemic absorption of
pathologic levels of ethanol production by dysregulated gut microbiota
explanation: >-
The cohort report explicitly defines the link between dysregulated gut
microbial production, systemic absorption, and intoxication.
- name: Systemic Ethanol Exposure
biological_scale: ORGANISM
mechanism_confidence: ESTABLISHED
description: >-
Absorbed endogenous ethanol raises blood and breath alcohol concentration
despite the absence of exogenous alcohol intake. The magnitude is variable;
confirmed cases can reach concentrations associated with clinically important
intoxication.
chemical_entities:
- preferred_term: ethanol
term:
id: CHEBI:16236
label: ethanol
modifier: INCREASED
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "his blood alcohol levels ranged from 50 to 400 mg/dL"
explanation: >-
A supervised clinical evaluation documented substantial systemic ethanol
concentrations in a confirmed ABS case.
downstream:
- target: Elevated Blood Ethanol Concentration
causal_link_type: DIRECT
description: >-
Systemic absorption of endogenous ethanol is measured as an elevated blood
alcohol concentration.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "his blood alcohol levels ranged from 50 to 400 mg/dL"
explanation: The case directly documents the laboratory phenotype.
- target: Ethanol Intoxication
causal_link_type: DIRECT
description: >-
Pharmacologically meaningful circulating ethanol causes the same acute
intoxication syndrome regardless of whether its source is endogenous or
exogenous.
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Auto-brewery syndrome (ABS) is a rarely diagnosed disorder of alcohol
intoxication due to gut microbial ethanol production.
explanation: >-
The cohort report directly links gut microbial ethanol production to the
intoxication syndrome.
- name: Ethanol Intoxication
biological_scale: ORGANISM
mechanism_confidence: ESTABLISHED
description: >-
Endogenous systemic ethanol produces episodic neurologic and gastrointestinal
manifestations typical of intoxication, including ataxia, slurred speech,
gait difficulty, confusion, memory impairment, and nausea. This node captures
the clinical effect of ethanol without asserting an ABS-specific receptor or
withdrawal mechanism that has not been tested.
biological_processes:
- preferred_term: response to ethanol
term:
id: GO:0045471
label: response to ethanol
modifier: INCREASED
chemical_entities:
- preferred_term: ethanol
term:
id: CHEBI:16236
label: ethanol
modifier: INCREASED
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: >-
The systematic review directly describes an intoxication-like symptom
complex in ABS/GFS cases.
downstream:
- target: Ataxia
causal_link_type: DIRECT
description: Ataxia occurs during endogenous ethanol intoxication.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: The systematic review directly lists ataxia.
- target: Dysarthria
causal_link_type: DIRECT
description: Slurred speech is a directly reported manifestation of ABS intoxication.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: The systematic review directly lists slurred speech.
- target: Gait Disturbance
causal_link_type: DIRECT
description: Intoxication-related imbalance can cause gait difficulty and falls.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most significant event caused by one of his inebriations was a fall
that caused intracranial bleeding
explanation: An ABS inebriation episode directly caused a serious fall.
- target: Confusion
causal_link_type: DIRECT
description: Confusional brain-fog episodes occur during ABS intoxication.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
personality changes with episodes of depression, ‘brain fog’, and
aggressive behaviour became apparent
explanation: A confirmed case directly reports brain-fog episodes.
- target: Memory Impairment
causal_link_type: DIRECT
description: Episodic memory loss is reported in confirmed ABS.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
He complained of having had memory loss, mental changes, and episodes of
depression for over 6 years
explanation: A confirmed case directly reports persistent episodic memory loss.
- target: Nausea
causal_link_type: DIRECT
description: Nausea is a directly reported symptom of ABS intoxication.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: The systematic review directly lists nausea.
biochemical:
- name: Blood Ethanol
presence: INCREASED
context: >-
A monitored rise in blood or breath ethanol without access to exogenous
alcohol is the central objective abnormality and the readout used during a
supervised glucose challenge.
biomarker_term:
preferred_term: ethanol
term:
id: CHEBI:16236
label: ethanol
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "his blood alcohol levels ranged from 50 to 400 mg/dL"
explanation: A confirmed case directly documents markedly increased blood ethanol.
- name: Fecal Acetate
presence: INCREASED
context: >-
Fecal acetate was increased in the observational cohort and correlated with
concurrent blood alcohol concentration. It is a research biomarker of altered
microbial metabolism, not a validated diagnostic test for ABS.
biomarker_term:
preferred_term: acetate
term:
id: CHEBI:30089
label: acetate
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Faecal metabolomics revealed increased acetate levels associated with ABS,
which correlated with blood alcohol concentrations.
explanation: >-
The cohort directly supports increased fecal acetate as a correlated research
readout.
phenotypes:
- name: Elevated Blood Ethanol Concentration
category: Laboratory
description: >-
Blood ethanol rises without exogenous alcohol consumption and can reach
concentrations associated with substantial intoxication.
phenotype_term:
preferred_term: Substantially elevated circulating ethanol concentration
term:
id: HP:6000986
label: Substantially elevated circulating ethanol concentration
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "his blood alcohol levels ranged from 50 to 400 mg/dL"
explanation: The case directly documents substantially elevated blood ethanol.
- name: Ataxia
category: Neurological
description: >-
Impaired coordination occurs during endogenous ethanol intoxication episodes.
phenotype_term:
preferred_term: Ataxia
term:
id: HP:0001251
label: Ataxia
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: The systematic review directly lists ataxia in GFS/ABS.
- name: Dysarthria
category: Neurological
description: Slurred speech is reported during ABS intoxication episodes.
phenotype_term:
preferred_term: Dysarthria
term:
id: HP:0001260
label: Dysarthria
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: The systematic review directly lists slurred speech.
- name: Gait Disturbance
category: Neurological
description: >-
Unsteady gait and falls can occur during ABS inebriation; serious fall injury
has been documented.
phenotype_term:
preferred_term: Gait disturbance
term:
id: HP:0001288
label: Gait disturbance
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most significant event caused by one of his inebriations was a fall
that caused intracranial bleeding
explanation: A confirmed ABS intoxication episode directly caused a fall.
- name: Confusion
category: Neurological
description: Brain fog and mental-status changes occur during symptomatic episodes.
phenotype_term:
preferred_term: Confusion
term:
id: HP:0001289
label: Confusion
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
personality changes with episodes of depression, ‘brain fog’, and
aggressive behaviour became apparent
explanation: A confirmed case directly reports brain fog and mental changes.
- name: Memory Impairment
category: Neurological
description: Memory loss has been directly reported in confirmed ABS.
phenotype_term:
preferred_term: Memory impairment
term:
id: HP:0002354
label: Memory impairment
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
He complained of having had memory loss, mental changes, and episodes of
depression for over 6 years
explanation: A confirmed ABS case directly reports memory loss.
- name: Nausea
category: Gastrointestinal
description: Nausea is reported as part of the intoxication-like symptom complex.
phenotype_term:
preferred_term: Nausea
term:
id: HP:0002018
label: Nausea
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptoms include decreased social inhibition, decreased peripheral vision,
ataxia, nausea, and slurred speech, similar to those of excessive alcoholic
consumption.
explanation: The systematic review directly lists nausea.
environmental:
- name: High Carbohydrate and Monosaccharide Exposure
exposure_term:
preferred_term: high dietary carbohydrate exposure
modifier: INCREASED
term:
id: ECTO:9000162
label: exposure to carbohydrate
influences_mechanisms:
- target: Excess Gut Microbial Ethanol Production
environmental_effect: TRIGGERS
causal_link_type: DIRECT
description: >-
Dietary carbohydrate is the substrate the gut organisms ferment, so it
is consumed by the node rather than acting on it from outside. Recorded
as direct on that basis, while noting that the cited case-control study
calls monosaccharide content a potential inducing factor rather than a
demonstrated one.
evidence:
- reference: PMID:37060744
reference_title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Monosaccharide content was identified as a potential food-related inducing factor for alcohol production."
explanation: >-
Case-control study of an auto-brewery cohort identifying
monosaccharide content as a potential food-related inducing factor for
alcohol production, the substrate step this link records.
description: >-
Dietary carbohydrate supplies substrate for microbial fermentation. Simple
sugar content is a plausible trigger for ethanol-production flares, although
individual tolerance and microbial substrate use vary.
evidence:
- reference: PMID:37060744
reference_title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Monosaccharide content was identified as a potential food-related inducing
factor for alcohol production.
explanation: The case-control study identifies monosaccharide content as a trigger.
- name: Prior Antibiotic Exposure
influences_mechanisms:
- target: Fungal Overgrowth in a Subset of Cases
environmental_effect: PREDISPOSES
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
description: >-
Antibiotics clear the bacteria that hold fungal populations in check,
and the fungi expand into the space left behind. The intervening loss of
colonization resistance is understood but is not measured here, and the
exposure preceded disease in only some reported cases, which is why the
link is graded predisposing and partial.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The disease is mostly reported by Saccharomyces and Candida genera, and some cases were previously treated with antibiotics."
explanation: >-
Systematic review of case reports noting that the fungal cases are
mostly Saccharomyces and Candida and that some had prior antibiotic
treatment. Some, not all, is the reason this stays partial.
description: >-
Antibiotic exposure preceded disease in a subset of reported fungal cases and
may disrupt colonization resistance. It is a risk context rather than a
necessary cause, and antibiotics can also be used therapeutically in bacterial
ABS.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease is mostly reported by Saccharomyces and Candida genera, and
some cases were previously treated with antibiotics.
explanation: The systematic review documents antecedent antibiotic use only in some cases.
- name: Gastrointestinal Obstruction or Hypomotility
description: >-
Chronic obstruction or hypomotility may favor microbial overgrowth and is a
recognized clinical context in which ABS should be considered, but it is not
present in every patient.
evidence:
- reference: PMID:34682761
reference_title: "The Auto-Brewery Syndrome: A Perfect Metabolic \"Storm\" with Clinical and Forensic Implications."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This syndrome should be considered in patients with chronic obstruction or
hypomotility presenting with elevated breath and blood alcohol concentrations
explanation: The review identifies obstruction and hypomotility as predisposing contexts.
diagnosis:
- name: Supervised Oral Glucose Challenge with Serial Ethanol Measurement
description: >-
The diagnostic cornerstone is a monitored rise in blood or breath ethanol in
a supervised setting, commonly after an oral glucose challenge. Baseline and
serial sampling may be required because ethanol production can be delayed.
Strict observation is essential to exclude exogenous alcohol ingestion.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: NCIT:C18020
label: Diagnostic Procedure
evidence:
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the gold standard for diagnosis consists of a monitored rise in blood
alcohol concentration while the patient is in a supervised clinical setting
and is typically facilitated with administration of an oral glucose load
explanation: >-
The current cohort report states the supervised blood-ethanol rise and oral
glucose load that define confirmation.
- name: Targeted Gastrointestinal Microbiology and Susceptibility Testing
description: >-
Stool culture or endoscopically obtained gastrointestinal secretions can help
identify bacterial or fungal contributors and guide susceptibility-based
therapy. Microbial detection is adjunctive: culture alone does not prove ABS
without a supervised endogenous ethanol rise.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: NCIT:C18020
label: Diagnostic Procedure
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The aim of this case report was confirmation and treatment of ABS using a
standardised carbohydrate challenge test followed by upper and lower
endoscopy to obtain intestinal secretions to detect fungal growth.
explanation: >-
The case demonstrates how endoscopic microbiology can complement a positive
supervised challenge and enable targeted treatment.
differential_diagnoses:
- name: Exogenous Alcohol Ingestion or Alcohol Use Disorder
description: >-
Surreptitious or unrecognized exogenous alcohol exposure is the most important
alternative explanation for intoxication and an elevated ethanol measurement.
Confirmation of ABS requires strict supervision during challenge testing and
exclusion of access to alcohol; symptoms and denial of use alone are not
diagnostic.
distinguishing_features:
- In ABS, ethanol rises under supervised alcohol-free conditions after a carbohydrate challenge.
- Exogenous intake is not explained by reproducible carbohydrate-triggered ethanol production under observation.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is important that the patients are strictly monitored during the test
for any consumption of alcoholic beverages, which would otherwise severely
bias the test.
explanation: >-
The systematic review identifies supervised exclusion of alcohol consumption
as essential to valid diagnosis.
treatments:
- name: Targeted Antibacterial Combination Therapy
action_category: THERAPEUTIC
therapeutic_modality: SMALL_MOLECULE
description: >-
For bacterial ABS, susceptibility-informed antibiotics may suppress
ethanol-producing pathobionts. Human outcome evidence is limited to small
cohorts and combination regimens, so antibiotic monotherapy cannot be assumed
effective and unnecessary broad-spectrum exposure may worsen dysbiosis.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: antibiotic
term:
id: NCIT:C258
label: Antibiotic
target_mechanisms:
- target: Flare-Associated Bacterial Gut Dysbiosis
treatment_effect: INHIBITS
description: Antibiotics suppress implicated ethanol-producing bacteria.
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Faecal samples from individuals with ABS during a flare produced more
ethanol in vitro, which could be reduced by antibiotic treatment.
explanation: The cohort directly shows reduced flare-sample ethanol production after antibiotic treatment.
evidence:
- reference: PMID:37060744
reference_title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatments with antibiotics, a complex probiotic preparation and a
low-carbohydrate diet not only alleviated ABS, but also erased ABS relapse
during the follow-up observation of one of the patients.
explanation: >-
The study supports an antibiotic-containing combination regimen in one
patient but does not isolate the antibiotic effect.
- name: Sensitivity-Guided Antifungal Therapy
action_category: THERAPEUTIC
therapeutic_modality: SMALL_MOLECULE
description: >-
When gastrointestinal fungi are recovered in a confirmed case, antifungal
selection should follow organism identification and susceptibility testing.
Evidence is case-based and should not be generalized to bacterial ABS.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: antifungal agent
term:
id: NCIT:C514
label: Antifungal Agent
target_mechanisms:
- target: Fungal Overgrowth in a Subset of Cases
treatment_effect: INHIBITS
description: Antifungal therapy suppresses cultured fermenting fungi.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatment with antifungal agents allowed subsequent ingestion of
carbohydrates without symptoms.
explanation: The case links antifungal treatment of fungal ABS to symptom-free carbohydrate ingestion.
evidence:
- reference: PMID:31423320
reference_title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatment with antifungal agents allowed subsequent ingestion of
carbohydrates without symptoms.
explanation: >-
A confirmed fungal case improved and tolerated carbohydrate after targeted
antifungal treatment.
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In five case reports, fluconazole 100 mg/day for 3 weeks and/or
low‐carbohydrate diet was sufficient to treat the GFS.
explanation: The systematic review documents successful case-based regimens.
- name: Low-Carbohydrate Dietary Intervention
action_category: THERAPEUTIC
therapeutic_modality: BEHAVIORAL
description: >-
Restricting fermentable carbohydrate reduces substrate for microbial ethanol
production. The approach is supported by case reports and combination
regimens; the optimal composition, duration, and reintroduction strategy are
not established.
treatment_term:
preferred_term: dietary intervention
term:
id: NCIT:C15447
label: Dietary Intervention
target_mechanisms:
- target: Excess Gut Microbial Ethanol Production
treatment_effect: INHIBITS
description: Reduced fermentable substrate limits microbial ethanol production.
evidence:
- reference: PMID:37060744
reference_title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Monosaccharide content was identified as a potential food-related inducing
factor for alcohol production.
explanation: Identifying monosaccharide substrate as an inducing factor supports dietary substrate restriction.
evidence:
- reference: PMID:33887125
reference_title: "Gut fermentation syndrome: A systematic review of case reports."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In five case reports, fluconazole 100 mg/day for 3 weeks and/or
low‐carbohydrate diet was sufficient to treat the GFS.
explanation: The systematic review supports low-carbohydrate treatment only at case-report level.
- name: Fecal Microbiota Transplantation for Refractory Disease
action_category: THERAPEUTIC
therapeutic_modality: OTHER
description: >-
Fecal microbiota transplantation (FMT) is an emerging microbiome-restoration
strategy for severe or refractory ABS. The largest cohort reports detailed
longitudinal improvement in one patient, followed by relapse after the first
FMT and a longer remission after a second, more intensive multicomponent
regimen. Efficacy and safety remain investigational.
treatment_term:
preferred_term: fecal microbiota transplantation
term:
id: NCIT:C118643
label: Fecal Microbiota Transplantation
target_mechanisms:
- target: Flare-Associated Bacterial Gut Dysbiosis
treatment_effect: RESTORES
description: FMT aims to restore a non-ethanol-producing microbial community.
evidence:
- reference: PMID:41507585
reference_title: "Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Finally, one patient was treated with faecal microbiota transplantation,
with positive correlations between gut microbiota composition and
function, and symptoms.
explanation: The single-patient analysis links FMT-associated microbiome changes with microbial function and symptoms.
evidence:
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After initial FMT, the patient experienced significant improvement in
symptoms and no detectable blood alcohol levels for 3 months.
explanation: >-
The cohort reports a clinically meaningful but single-patient response.
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Unfortunately, his symptoms relapsed after this initial period of remission."
explanation: >-
Relapse after the first procedure limits any efficacy conclusion and supports
investigational framing.
animal_models:
- species: Mus musculus
category: Microbiome transfer model
description: >-
High-alcohol-producing Klebsiella species isolated from patients with ABS
induced an ABS-like ethanol-production phenotype in mice. This supports
microbial causality for bacterial ABS but does not establish that Klebsiella
explains all human cases.
associated_phenotypes:
- Endogenous ethanol production
- Elevated blood alcohol concentration
evidence:
- reference: PMID:37060744
reference_title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We isolated three species of HiAlc Klebsiella from ABS patients, which were
able to induce ABS in mice.
explanation: Patient-derived bacterial isolates reproduced an ABS-like phenotype in mice.
clinical_trials:
- name: NCT06083142
phase: PHASE_I
status: ACTIVE_NOT_RECRUITING
description: >-
Early-phase study of oral FMT capsules in people with diagnosed ABS. After an
antibiotic and bowel-cleansing preparation, participants receive five capsule
doses over one week and are followed for safety, feasibility, and research
samples. The estimated enrollment is eight.
review_notes: >-
ClinicalTrials.gov reports the phase as EARLY_PHASE1; the schema's closest
available value is PHASE_I. Registry status was ACTIVE_NOT_RECRUITING when
reviewed on 2026-07-20, with estimated completion in 2030.
evidence:
- reference: clinicaltrials:NCT06083142
reference_title: Fecal Microbiota Transplant for Autobrewery Syndrome
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The goal of this clinical trial is to study fecal microbiota
transplantation(FMT) by oral capsule in people already diagnosed with
auto-brewery syndrome (ABS, also known as gut fermentation syndrome).
explanation: The registry documents the investigational oral-FMT intervention and population.
datasets:
- accession: bioproject:PRJNA1257465
title: Auto-brewery syndrome flare, remission, household-partner, and FMT microbiome sequencing
description: >-
Public shotgun metagenomic and ITS2 sequencing from the 2026 observational
cohort, including ABS flare and remission samples, unaffected household
partners, and longitudinal samples around FMT. The associated metabolomics
are available only on request and are not represented by this public SRA
accession.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: WGS
sample_types:
- preferred_term: feces
term:
id: UBERON:0001988
label: feces
tissue_term:
preferred_term: feces
term:
id: UBERON:0001988
label: feces
sample_count: 87
conditions:
- ABS flare
- ABS remission
- unaffected household partner
- before and after fecal microbiota transplantation
platform: Illumina NovaSeq X Plus, paired-end 150 bp
publication: PMID:41507585
evidence:
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Shotgun metagenomics and ITS2 sequencing datasets have been uploaded to the
Sequence Read Archive (SRA) under BioProject accession number PRJNA1257465.
explanation: The publication's data-availability statement identifies the public accession.
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13244660/
reference_title: "Gut microbial ethanol metabolism contributes to Auto-brewery Syndrome in an observational cohort - PMC"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A total of 87 samples were sequenced, including 21 samples from household
partners, 22 samples from patients with ABS in remission, 26 samples from
patients during a flare, and an additional 18 samples from our FMT patient
and household partner during and after FMTs.
explanation: The methods give the exact sample count and clinical-condition breakdown.
notes: >-
The bacterial mechanism has the strongest current cohort-level support. Fungal
ABS remains credible for selected culture-confirmed cases but should not be
assumed from the syndrome name or treated empirically without microbiologic
support. A probiotic was used in combination regimens, but its independent
benefit has not been studied. The public dataset contains sequencing data;
metabolomics from the 2026 cohort are available only on request.
review_notes: >-
Full evidence and ontology review completed 2026-07-20. Preserved the existing
deprecated updated_date at task direction. Removed unsupported phenotype
frequencies, a speculative impaired-hepatic-clearance node, extrapolated
receptor-level ethanol pharmacology, withdrawal-based seizure claims, and
standalone probiotic therapy. Trial status and public data availability were
checked against current primary sources.
references:
- reference: PMID:41507585
title: Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort.
findings: []
- reference: PMID:37060744
title: "Three Klebsiella species as potential pathobionts generating endogenous ethanol in a clinical cohort of patients with auto-brewery syndrome: a case control study."
findings: []
- reference: PMID:33887125
title: "Gut fermentation syndrome: A systematic review of case reports."
findings: []
- reference: PMID:31423320
title: "Case report and literature review of auto-brewery syndrome: probably an underdiagnosed medical condition."
findings: []
Auto-brewery syndrome (ABS), also known as gut fermentation syndrome or endogenous ethanol fermentation, represents a rare and often underdiagnosed medical condition in which intoxicating quantities of ethanol are produced through endogenous fermentation of carbohydrates within the gastrointestinal tract, oral cavity, or urinary system[paramsothy-2023-abs-review-abstract]. Patients with this condition present with signs and symptoms of alcohol intoxication despite denying alcohol consumption, creating significant clinical, social, and legal challenges[dinis-oliveira-2021-metabolic-storm-abstract]. The syndrome was first documented in 1948 with a case describing fatal gastric rupture in a five-year-old African child, and Japanese literature documented instances under the term "Meitei-sho" during the 1970s[dinis-oliveira-2021-metabolic-storm-abstract].
The pathophysiology of ABS involves a "perfect metabolic storm" whereby gut dysbiosis—particularly fungal or bacterial overgrowth—combined with high carbohydrate intake and potentially impaired hepatic ethanol metabolism results in accumulation of endogenous ethanol to levels that produce clinical intoxication[dinis-oliveira-2021-metabolic-storm-summary]. While historically attributed primarily to fungal organisms, particularly Candida and Saccharomyces species, recent research has identified bacterial causes including high-alcohol-producing Klebsiella pneumoniae strains, expanding our understanding of this complex syndrome[zhu-2023-klebsiella-abs-abstract]. This review synthesizes current knowledge on the molecular mechanisms, genetic factors, clinical manifestations, and therapeutic approaches relevant to ABS.
The causative organisms in auto-brewery syndrome span both fungal and bacterial kingdoms, reflecting the diverse microorganisms capable of fermenting carbohydrates to ethanol within the human gastrointestinal tract. A systematic review by Bayoumy and colleagues analyzing 17 case reports covering 20 patients found that the microorganisms identified were usually from the Saccharomyces and Candida genera[bayoumy-2021-gfs-systematic-review-abstract]. The complete spectrum of identified causative organisms includes the yeasts Saccharomyces cerevisiae (brewer's yeast, the most commonly implicated organism), Saccharomyces boulardii (notably a probiotic yeast), Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, Candida kefyr, Candida parapsilosis, and Kluyveromyces marxianus[paramsothy-2023-abs-review-abstract][dinis-oliveira-2021-metabolic-storm-abstract].
The bacterial causes of ABS have gained increasing recognition following landmark work by Yuan and colleagues demonstrating that high-alcohol-producing Klebsiella pneumoniae (HiAlc Kpn) is associated with up to 60% of individuals with non-alcoholic fatty liver disease (NAFLD) in Chinese cohorts[yuan-2019-klebsiella-nafld-abstract]. Subsequent research by Zhu and colleagues identified three Klebsiella species—K. pneumoniae, K. quasipneumoniae, and K. variicola—as potential pathobionts capable of generating endogenous ethanol in ABS patients, with alcohol concentrations reaching 300-400 mg/dL during episodes, equivalent to approximately 15 shots of 40% whisky[zhu-2023-klebsiella-abs-abstract]. Additional bacterial organisms implicated in individual cases include Enterococcus faecium, Enterococcus faecalis, and Citrobacter freundii[dinis-oliveira-2021-metabolic-storm-abstract].
Most yeasts possess the capability to ferment sugars anaerobically, but species such as Candida glabrata and Saccharomyces cerevisiae exhibit an additional adaptation known as the Crabtree effect, enabling them to ferment sugars even in the presence of oxygen[dinis-oliveira-2021-metabolic-storm-summary]. This evolutionary adaptation allows these organisms to suppress the growth of competing microorganisms and may explain why pathological fermentation can occur even in the relatively aerobic environment of the upper gastrointestinal tract.
The primary mechanism of ethanol production in fungal ABS involves the classical alcoholic fermentation pathway. Glucose is transported into microbial cells via hexose transporters, then metabolized through glycolysis to pyruvate[dinis-oliveira-2021-metabolic-storm-abstract]. Under anaerobic or microaerobic conditions, pyruvate undergoes decarboxylation to acetaldehyde, a reaction catalyzed by pyruvate decarboxylase (PDC), a thiamine pyrophosphate-dependent enzyme. In Saccharomyces cerevisiae, this enzyme is encoded by three genes—PDC1, PDC5, and PDC6—with Pdc1p and Pdc5p being the primary active isoforms during fermentation. The acetaldehyde is then reduced to ethanol by alcohol dehydrogenase (ADH), regenerating NAD+ in the process to sustain continued glycolysis.
In Candida albicans, alcohol dehydrogenase I encoded by the ADH1 gene serves as a key enzyme catalyzing the conversion of acetaldehyde to ethanol. Research has demonstrated that ADH1 promotes C. albicans pathogenicity through effects on oxidative phosphorylation, and deletion of ADH1 significantly affects mitochondrial membrane potential and intracellular ATP content. Interestingly, transcriptional regulators Gal4p and Tye7p have been shown to bind to and activate genes involved in fermenting pyruvate to ethanol, including PDC11, ADH1, and NDE1, indicating coordinated regulation of the entire fermentation pathway from glucose to ethanol.
Bacterial ABS, particularly that caused by Klebsiella species, employs a distinct metabolic pathway centered on the 2,3-butanediol fermentation system. Research by Li and colleagues demonstrated that carbohydrate substances are catabolized to produce both alcohol and 2,3-butanediol via this pathway, with ethanol arising as a byproduct[li-2021-klebsiella-23butanediol-abstract]. The pathway involves three critical enzymatic steps: first, alpha-acetolactate synthase (encoded by budB) catalyzes the condensation of two pyruvate molecules to form alpha-acetolactate with CO2 release; second, alpha-acetolactate decarboxylase (encoded by budA) converts alpha-acetolactate to acetoin; and third, 2,3-butanediol dehydrogenase (encoded by budC), also known as acetoin reductase, reduces acetoin to 2,3-butanediol.
Genomic analysis of HiAlc Kpn strains W14 and TH1 revealed that these organisms possess 12 copies of alcohol dehydrogenase (ADH) genes, significantly exceeding standard strains, enabling ethanol production up to 83.7 mmol/L under aerobic conditions[li-2021-klebsiella-23butanediol-abstract]. Proteomic analysis demonstrated that 10 proteins and six major metabolites involved in the 2,3-butanediol fermentation pathway exhibited at least a three-fold change in HiAlc strains. Importantly, this pathway operates under both aerobic and anaerobic conditions, though aerobic conditions yield higher alcohol production, explaining why gut fermentation can occur throughout the gastrointestinal tract.
Validation of this pathway was achieved through experiments with triazolopyrimidine, an inhibitor of alpha-acetolactate synthetase, which reduced alcohol production to below 10 mg/mL with IC50 values of 42.6-43.7 µM[li-2021-klebsiella-23butanediol-abstract]. Additionally, construction of ADH gene knockout mutants (W14-Δadh) demonstrated minimal pathological changes compared to wild-type strains, confirming the essential role of alcohol dehydrogenase in the disease process.
The severity and clinical presentation of ABS may be significantly influenced by host genetic factors affecting ethanol metabolism. The primary pathway of ethanol clearance involves two enzymatic steps: oxidation of ethanol to acetaldehyde by alcohol dehydrogenase (ADH), followed by oxidation of acetaldehyde to acetate by aldehyde dehydrogenase (ALDH)[edenberg-2007-adh-aldh-genetics-abstract]. Polymorphisms in genes encoding these enzymes can substantially alter the kinetics of ethanol and acetaldehyde metabolism.
Humans possess seven ADH genes (ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7) clustered on chromosome 4, with Class I enzymes (encoded by ADH1A, ADH1B, and ADH1C) accounting for approximately 70% of hepatic ethanol-oxidizing capacity[edenberg-2007-adh-aldh-genetics-abstract]. The ADH1B2 allele, common in East Asian populations, encodes an enzyme with 70-80 fold higher turnover compared to the reference allele, resulting in more rapid conversion of ethanol to acetaldehyde. The ADH1B3 allele, found primarily in African populations, also demonstrates enhanced activity.
The mitochondrial aldehyde dehydrogenase ALDH2, encoded on chromosome 12, plays the predominant role in acetaldehyde clearance. The ALDH22 variant, resulting from a lysine substitution at position 504, produces an essentially inactive enzyme with nearly dominant inheritance in heterozygotes[edenberg-2007-adh-aldh-genetics-abstract]. This variant is essentially only found in Asian populations, with approximately 50% of East Asians lacking functional ALDH2 activity. Individuals with ALDH22 accumulate acetaldehyde, leading to the characteristic "Asian flush" reaction characterized by facial flushing, nausea, and tachycardia—effects that parallel disulfiram (Antabuse) administration.
In the context of ABS, individuals with genetic polymorphisms of ADH and ALDH may find it more difficult to metabolize endogenous ethanol, potentially worsening intoxication symptoms[paramsothy-2023-abs-review-abstract]. Those with highly active ADH variants may rapidly generate acetaldehyde but, if they also carry ALDH2*2, cannot efficiently clear this toxic intermediate. Conversely, individuals with less active ADH variants may have prolonged ethanol half-life, allowing greater accumulation from even modest endogenous production rates. These genetic considerations underscore the importance of personalized assessment in ABS management.
Auto-brewery syndrome develops through a confluence of factors that create the "perfect metabolic storm"—intestinal dysbiosis, substrate availability, and impaired clearance mechanisms[dinis-oliveira-2021-metabolic-storm-summary]. The condition is more prevalent in patients with comorbidities including diabetes mellitus, obesity, liver cirrhosis, Crohn's disease, and short bowel syndrome, though it can occur in otherwise healthy individuals[paramsothy-2023-abs-review-abstract].
Antibiotic exposure represents a critical precipitating factor, with five of 17 case reports in the systematic review by Bayoumy describing recent antibiotic use before or at onset of symptoms[bayoumy-2021-gfs-systematic-review-abstract]. Antibiotics disrupt the protective commensal microbiota, potentially allowing colonization and overgrowth of alcohol-producing species. The case reported by Spinucci and colleagues elegantly demonstrated this mechanism: a patient with chronic intestinal pseudo-obstruction developed ABS specifically following amoxicillin-clavulanic acid treatment combined with a simple sugar-rich diet, with blood ethanol disappearing within 24 hours of discontinuing both factors and reappearing upon rechallenge[spinucci-2006-pseudoobstruction-abstract].
Gastrointestinal anatomical abnormalities predispose to ABS by creating conditions favoring microbial stagnation and overgrowth. These include short bowel syndrome resulting from surgical resection, chronic intestinal pseudo-obstruction, gastric bypass and other bariatric procedures, and any condition causing intestinal dysmotility. In short bowel syndrome, the reduced absorptive capacity means that undigested carbohydrates reach the colon in excessive quantities, providing abundant substrate for fermentation. A case of a 3-year-old girl with short bowel syndrome documented by Jansson-Nettelbladt demonstrated blood ethanol concentrations of 15 mmol/L associated with introduction of a carbohydrate-rich fruit drink, leading the authors to recommend adding ABS to the differential diagnosis for D-lactic acidosis in SBS patients[jansson-nettelbladt-2006-sbs-child-abstract].
Hepatic dysfunction impairs the first-pass metabolism that normally clears endogenous ethanol before it reaches systemic circulation. The liver efficiently clears ethanol through ADH-mediated oxidation following Michaelis-Menten kinetics with a Km of 0.05-0.10 g/L, but this protective mechanism fails when ethanol production exceeds hepatic clearance capacity or when hepatic function is compromised[dinis-oliveira-2021-metabolic-storm-summary]. Studies by Hafez and colleagues confirmed that blood ethanol levels were significantly higher in patients with liver cirrhosis and diabetes mellitus compared to healthy controls after 12-hour fasting, suggesting differential susceptibility to endogenous ethanol accumulation[hafez-2017-endogenous-ethanol-abstract].
The development of auto-brewery syndrome follows a characteristic sequence of pathophysiological events that can be conceptualized as distinct phases progressing from predisposition to full clinical manifestation. Recent literature from Stamation (2025) identifies multiple interconnected mechanisms including gut dysbiosis, impaired intestinal barrier function, and dysregulation of the hypothalamic-pituitary-adrenal axis that collectively contribute to disease development[stamation-2025-alimentary-tract-ethanol-abstract].
The initial phase involves disruption of the normal gut microbiome, most commonly triggered by antibiotic exposure, which eliminates protective commensal bacteria and creates ecological niches for opportunistic colonization by fermentative organisms. This antibiotic-induced dysbiosis reduces colonization resistance, the phenomenon whereby resident microbiota prevent establishment of pathogenic organisms through nutrient competition, production of antimicrobial metabolites, and maintenance of intestinal immune homeostasis. Short-chain fatty acids (SCFAs) produced by gut bacterial fermentation have been found to inhibit the growth of Candida albicans through stimulation of intestinal mucosal immunity, and their depletion following antibiotic exposure facilitates fungal overgrowth.
The second phase involves establishment and proliferation of ethanol-producing microorganisms. Yeasts such as Saccharomyces cerevisiae and Candida species, or bacteria such as Klebsiella pneumoniae, colonize the intestinal lumen and begin metabolizing available carbohydrates. The Crabtree effect exhibited by certain yeasts allows them to perform alcoholic fermentation even in the presence of oxygen, conferring competitive advantage by producing ethanol that suppresses growth of competing microorganisms[tamama-2024-bladder-gut-fermentation-abstract]. This phase may be asymptomatic if ethanol production remains below hepatic clearance capacity.
The third phase represents the transition to clinical disease, occurring when endogenous ethanol production exceeds the liver's first-pass metabolic capacity. This tipping point may be reached through increased microbial burden, consumption of carbohydrate-rich meals providing abundant fermentation substrate, or compromise of hepatic function due to underlying liver disease. Once ethanol enters systemic circulation in quantities sufficient to produce detectable blood alcohol concentrations, the characteristic neurological, gastrointestinal, and behavioral symptoms manifest.
The fourth phase involves chronic exposure consequences if the condition remains undiagnosed or inadequately treated. Persistent endogenous ethanol production can lead to hepatic steatosis progressing to steatohepatitis, particularly when ethanol reaches the liver directly through the portal circulation[yuan-2019-klebsiella-nafld-abstract]. Furthermore, coupled with microbiota dysbiosis and oxidative stress, endogenous alcohol may contribute to lipid oxidation and fibrosis in liver disease. As hepatic function decreases, the liver's ability to metabolize ethanol also decreases, potentially creating a positive feedback loop that exacerbates the condition. Long-term exposure may also result in cravings for and addiction to alcohol, with subsequent development of alcohol use disorder.
A novel trigger recently identified in the literature is viral infection, specifically COVID-19. A 2024 case report documented development of ABS approximately one month following recovery from SARS-CoV-2 infection, with the authors hypothesizing that the virus altered gut microbiome composition to favor fermentation-capable organisms[COVID19-abs-2024-abstract]. This represents an emerging area requiring further investigation as post-viral dysbiosis becomes increasingly recognized.
The clinical presentation of auto-brewery syndrome encompasses neurological, gastrointestinal, psychological, and systemic manifestations that can profoundly impact patients' quality of life and social functioning. The neurological symptoms dominate the clinical picture and directly mirror those of exogenous alcohol intoxication: memory loss, mental status changes, recurrent seizures, slurred speech, incoherent speech, blurred vision, dizziness, disorientation, and ataxia with poor coordination leading to falls[paramsothy-2023-abs-review-abstract][dinis-oliveira-2021-metabolic-storm-abstract].
In the systematic review by Bayoumy and colleagues, the most common presenting symptoms included slurred speech (5 of 20 patients, 25%), walking difficulties (5 patients, 25%), intoxication without alcohol consumption (7 patients, 35%), fruity breath odor (3 patients, 15%), and seizures (2 patients, 10%)[bayoumy-2021-gfs-systematic-review-abstract]. The gastrointestinal manifestations include bloating, belching, nausea, vomiting, diarrhea, generalized abdominal discomfort, and symptoms consistent with irritable bowel syndrome[dinis-oliveira-2021-metabolic-storm-abstract]. Psychological and behavioral symptoms encompass depression, bizarre behavior, somnolence, disorientation, fatigue, and aggression.
The blood alcohol concentrations achieved in ABS can be remarkably high. One documented case registered an ethanol concentration greater than 400 mg/dL following carbohydrate consumption, and the Klebsiella-associated cases described by Zhu reached 300-400 mg/dL during episodes[zhu-2023-klebsiella-abs-abstract]. These levels contrast sharply with normal endogenous ethanol production, which ranges from 0 to 0.0008 g/L with median levels of approximately 0.00113 g/L in healthy individuals[dinis-oliveira-2021-metabolic-storm-abstract]. Mouse model experiments confirmed that portal vein blood ethanol concentrations in animals colonized with HiAlc Klebsiella were two times higher than peripheral blood, confirming gut microbial production[li-2021-klebsiella-23butanediol-abstract].
Long-term consequences of untreated ABS can include hepatic steatosis progressing to steatohepatitis, particularly in cases caused by HiAlc Klebsiella where the endogenous ethanol directly reaches the liver through the portal circulation[yuan-2019-klebsiella-nafld-abstract]. Furthermore, chronic exposure to endogenous ethanol may result in cravings for and addiction to alcohol, with subsequent development of alcohol use disorder during or after treatment[dinis-oliveira-2021-metabolic-storm-abstract].
Diagnosis of auto-brewery syndrome requires a high index of clinical suspicion combined with systematic evaluation to confirm endogenous ethanol production and exclude alternative explanations. The diagnostic workup begins with comprehensive history-taking, including detailed dietary habits, alcohol consumption patterns (with corroboration from family members), gastrointestinal symptoms, antibiotic exposure, and episodes of unexplained intoxication[paramsothy-2023-abs-review-abstract]. Physical examination assesses for signs of intoxication including alcohol-scented breath, glassy eyes, ataxia, and altered mental status.
Laboratory evaluation includes complete blood count, comprehensive metabolic panel, blood alcohol concentration, drug screening, and stool cultures for both bacterial and fungal organisms. Upper and lower endoscopy with collection of intestinal secretions from the stomach, small intestine, and cecum for culture helps identify the causative organism and guide antifungal or antibiotic therapy selection[malik-2019-abs-case-report-abstract].
The carbohydrate challenge test represents the definitive diagnostic procedure. The protocol involves patient preparation with 48-hour alcohol abstinence and 8-hour fasting, followed by baseline blood alcohol measurement[paramsothy-2023-abs-review-abstract]. The patient then receives 100-200 grams of oral glucose, with blood alcohol concentration and breath alcohol concentration measured at intervals of 0, 0.5, 1, 2, 4, 8, 16, and 24 hours[dinis-oliveira-2021-metabolic-storm-abstract]. Significant elevation of blood alcohol in the absence of exogenous alcohol consumption confirms the diagnosis. This testing should be conducted under observation to exclude covert alcohol consumption.
Differential diagnoses that must be excluded include irritable bowel syndrome, small intestinal bacterial overgrowth, hepatic encephalopathy, alcohol use disorder, psychiatric disorders, and importantly in short bowel syndrome patients, D-lactic acidosis[paramsothy-2023-abs-review-abstract][kowlgi-2015-dlactic-acidosis-abstract]. D-lactic acidosis shares the clinical presentation of encephalopathy, slurred speech, and ataxia with ABS, but is distinguished by the presence of metabolic acidosis and elevated D-lactate levels rather than elevated ethanol.
Treatment of auto-brewery syndrome requires a multifaceted approach combining dietary modification, antimicrobial therapy, microbiome restoration, and long-term maintenance strategies. Dietary modification forms the foundation of management: low-carbohydrate and sugar-restricted diets are essential for reducing fermentable substrates available to pathogenic microorganisms[paramsothy-2023-abs-review-abstract]. Recommendations include high-protein diets emphasizing quality meats, eggs, almonds, oats, cheese, Greek yogurt, and low-starch vegetables, with initial complete carbohydrate elimination for approximately 6 weeks before gradual reintroduction under nutritionist guidance[dinis-oliveira-2021-metabolic-storm-abstract].
Pharmacological management targets eradication of the causative organisms. For fungal ABS, fluconazole 100-150 mg daily for 14 days represents first-line therapy[paramsothy-2023-abs-review-abstract]. Second-line options include nystatin 500,000 IU three times daily for 10 days, which can be combined with fluconazole when resistance is suspected. For refractory cases, intravenous micafungin 150 mg for 6 weeks has been used successfully. Selection among antifungal classes—azoles, polyenes, and echinocandins—should be guided by culture and sensitivity results from endoscopic specimens[malik-2019-abs-case-report-abstract].
For bacterial ABS, particularly that caused by Klebsiella species, appropriate antibiotic therapy guided by sensitivity testing is indicated. Zhu and colleagues successfully treated a patient with HiAlc Klebsiella-associated ABS using levofloxacin combined with amino acid and vitamin C supplementation, achieving symptom-free status maintained during one-year follow-up[zhu-2023-klebsiella-abs-abstract].
Probiotic therapy aims to restore healthy gut microbiome composition and provide competitive inhibition of pathogenic organisms. Lactobacillus acidophilus (3 billion colony-forming units) used concurrently with antifungals has shown benefit, with multi-strain probiotic supplements recommended for long-term maintenance, sometimes continued for up to 1.5 years[paramsothy-2023-abs-review-abstract]. For bacterial ABS, complex probiotic preparations containing Lactobacillus species and Clostridium butyricum have demonstrated efficacy[zhu-2023-klebsiella-abs-abstract].
Fecal microbiota transplantation (FMT) has emerged as a promising option for refractory cases. One documented case demonstrated that a 47-year-old man treated with FMT for ABS remained symptom-free for 36 months[paramsothy-2023-abs-review-abstract]. The procedure aims to restore normal gut microbiome composition and diversity, displacing pathogenic fermentative organisms, though more research is needed to establish standardized protocols and long-term safety profiles.
Bladder fermentation syndrome (BFS), also termed urinary auto-brewery syndrome, represents a recently recognized related condition in which ethanol is produced within the urinary bladder rather than the gastrointestinal tract. The first experimentally-proven case was reported in 2020 by Kruckenberg and colleagues, describing a patient with poorly controlled diabetes who failed alcohol abstinence monitoring during liver transplant evaluation despite consistent denial of alcohol consumption[tamama-2024-bladder-gut-fermentation-abstract].
The pathophysiology of BFS differs fundamentally from gut fermentation syndrome in several respects. BFS requires three prerequisite conditions: hyperglycosuria providing glucose substrate, colonization by Crabtree-positive yeast (predominantly Candida glabrata), and the presence of oxygen in the bladder lumen (typically 4-40 mmHg). Notably, C. glabrata is phylogenetically closer to Saccharomyces cerevisiae than to Candida albicans, and like brewer's yeast, it exhibits the Crabtree effect—the ability to perform alcoholic fermentation even in the presence of adequate oxygen[tamama-2024-bladder-gut-fermentation-abstract]. This distinguishes it from other common urinary Candida species (C. albicans, C. tropicalis), which are Crabtree-negative and therefore unlikely to cause bladder fermentation.
A crucial distinguishing feature of BFS is the absence of systemic intoxication. The transitional epithelium lining the urinary bladder provides an effective barrier to ethanol absorption, in contrast to the highly permeable columnar epithelium of the intestine. Thus, while patients with BFS produce ethanol detectable in urine, they do not experience the neurological or behavioral symptoms characteristic of gut fermentation syndrome. This has profound implications for alcohol abstinence monitoring, as patients may repeatedly test positive for urinary ethanol without any clinical intoxication, leading to misdiagnosis as alcohol use disorder and potential disqualification from organ transplantation.
Diagnosis of BFS involves demonstrating positive urinary glucose and ethanol, negative serum ethanol metabolites (ethyl glucuronide, ethyl sulfate), and presence of yeast in urinalysis. A simplified diagnostic approach involves incubating a fresh urine sample at 37°C and demonstrating additional ethanol production over time. Treatment requires a two-pronged approach: optimizing glycemic control to reduce hyperglycosuria, and antifungal therapy. Importantly, SGLT2 inhibitors, increasingly used in diabetes management, may paradoxically worsen BFS by increasing urinary glucose excretion[tamama-2024-bladder-gut-fermentation-abstract].
Beyond diagnostic implications, BFS carries potential health consequences. Acetaldehyde, produced as an intermediate in the fermentation pathway, is a known carcinogen, raising concerns about increased bladder cancer risk in patients with chronic BFS. This represents an important area for future epidemiological investigation.
The following genes are relevant to auto-brewery syndrome pathophysiology:
Host Genes: - ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7 (HGNC:249-255) - Alcohol dehydrogenase family encoding enzymes catalyzing ethanol to acetaldehyde conversion - ALDH2 (HGNC:404) - Aldehyde dehydrogenase 2, mitochondrial; catalyzes acetaldehyde to acetate conversion - ALDH1A1 (HGNC:402) - Aldehyde dehydrogenase 1A1, cytosolic; secondary acetaldehyde metabolism
Microbial Genes (Saccharomyces cerevisiae): - PDC1, PDC5, PDC6 - Pyruvate decarboxylase isoforms - ADH1-ADH5 - Yeast alcohol dehydrogenase genes
Microbial Genes (Klebsiella pneumoniae): - budB - Alpha-acetolactate synthase - budA - Alpha-acetolactate decarboxylase - budC - 2,3-butanediol dehydrogenase (acetoin reductase) - ADH genes (multiple copies in HiAlc strains)
Neurological Phenotypes: - HP:0001250 - Seizures - HP:0001260 - Dysarthria (slurred speech) - HP:0002066 - Gait ataxia - HP:0001288 - Gait disturbance - HP:0000738 - Hallucinations - HP:0001289 - Confusion - HP:0002354 - Memory impairment - HP:0000739 - Anxiety - HP:0000716 - Depression - HP:0001259 - Coma
Gastrointestinal Phenotypes: - HP:0002013 - Vomiting - HP:0002014 - Diarrhea - HP:0002017 - Nausea - HP:0003270 - Abdominal distension (bloating) - HP:0002020 - Gastroesophageal reflux - HP:0012378 - Fatigue
Metabolic Phenotypes: - HP:0003076 - Glycosuria (in diabetic comorbidity) - HP:0001397 - Hepatic steatosis
Primary Metabolites: - CHEBI:16236 - Ethanol - CHEBI:15343 - Acetaldehyde - CHEBI:30089 - Acetate
Pathway Intermediates: - CHEBI:15361 - Pyruvate - CHEBI:17234 - Glucose - CHEBI:16108 - 2,3-Butanediol - CHEBI:15688 - Acetoin - CHEBI:16015 - Alpha-acetolactate
Cofactors: - CHEBI:15846 - NAD+ - CHEBI:16908 - NADH - CHEBI:9532 - Thiamine pyrophosphate (TPP) - CHEBI:18420 - Mg2+
Therapeutic Agents: - CHEBI:46081 - Fluconazole - CHEBI:7660 - Nystatin - CHEBI:600636 - Micafungin - CHEBI:4911 - Itraconazole
Several significant gaps remain in our understanding of auto-brewery syndrome that warrant further investigation:
True Prevalence: The actual prevalence of ABS remains unknown due to absence of standardized diagnostic criteria and likely significant underdiagnosis. Population-based studies using validated diagnostic protocols are needed to establish the true burden of this condition.
Microbiome Determinants: What specific microbiome configurations predispose to pathological fermentation? Research is needed to identify microbial signatures predictive of ABS risk and to understand why only some individuals with dysbiosis develop symptomatic ethanol production.
Genetic Susceptibility: While ADH and ALDH polymorphisms affect ethanol metabolism, their specific contribution to ABS susceptibility and severity has not been systematically studied. Genome-wide association studies in ABS cohorts could identify additional genetic risk factors.
Fermentation Site Localization: Current understanding suggests fermentation occurs primarily in the small intestine and cecum, but the precise anatomical localization may vary by causative organism. Non-invasive imaging or biomarker approaches to localize fermentation would improve therapeutic targeting.
Bacterial vs. Fungal Pathophysiology: The relative contributions of bacterial and fungal organisms to the overall ABS burden remain unclear. The discovery of HiAlc Klebsiella species raises questions about whether bacterial causes have been historically underrecognized.
Long-term Hepatic Consequences: The connection between ABS and NAFLD/NASH progression requires longitudinal study. Does chronic subclinical endogenous ethanol production contribute to metabolic liver disease in the broader population?
Optimal Treatment Duration: Current treatment protocols are empirically derived from case reports. Randomized controlled trials are needed to establish optimal antifungal/antibiotic duration, dietary restriction duration, and probiotic supplementation regimens.
FMT Standardization: Fecal microbiota transplantation shows promise for refractory cases, but optimal donor selection, preparation methods, and delivery routes remain undefined for this indication.
Pediatric Considerations: ABS in children with predisposing conditions (short bowel syndrome, congenital intestinal abnormalities) may have distinct features requiring age-specific diagnostic and therapeutic approaches.
Medicolegal Framework: The forensic and legal implications of ABS require clearer guidelines for courts evaluating claims of endogenous intoxication in DUI and related cases.
paramsothy-2023-abs-review - Paramsothy J, Gutlapalli SD, et al. Understanding Auto-Brewery Syndrome in 2023: A Clinical and Comprehensive Review of a Rare Medical Condition. Cureus. 2023;15(4):e37678. PMID: 37206535. PMCID: PMC10189828. DOI: 10.7759/cureus.37678. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10189828/
bayoumy-2021-gfs-systematic-review - Bayoumy AB, Mulder I, Nauta A, Touw DJ, Mulder CJJ. Gut Fermentation Syndrome: A Systematic Review of Case Reports. United European Gastroenterology Journal. 2021;9(3):332-342. PMID: 33887125. PMCID: PMC8259373. DOI: 10.1002/ueg2.12062. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8259373/
dinis-oliveira-2021-metabolic-storm - Dinis-Oliveira RJ. The Auto-Brewery Syndrome: A Perfect Metabolic "Storm" with Clinical and Forensic Implications. Journal of Clinical Medicine. 2021;10(20):4637. PMID: 34682761. PMCID: PMC8537665. DOI: 10.3390/jcm10204637. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8537665/
malik-2019-abs-case-report - Malik F, Wickremesinghe P, Saverimuttu J. Case Report and Literature Review of Auto-Brewery Syndrome: Probably an Underdiagnosed Medical Condition. BMJ Open Gastroenterology. 2019;6(1):e000325. PMID: 31423320. PMCID: PMC6688699. DOI: 10.1136/bmjgast-2019-000325. URL: https://pubmed.ncbi.nlm.nih.gov/31423320/
yuan-2019-klebsiella-nafld - Yuan J, Chen C, Cui J, et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metabolism. 2019;30(4):675-688.e7. PMID: 31543403. DOI: 10.1016/j.cmet.2019.08.018. URL: https://pubmed.ncbi.nlm.nih.gov/31543403/
zhu-2023-klebsiella-abs - Zhu F, Yuan J, Chen C, et al. Three Klebsiella Species as Potential Pathobionts Generating Endogenous Ethanol in a Clinical Cohort of Patients with Auto-Brewery Syndrome: A Case Control Study. eBioMedicine. 2023;91:104560. PMID: 37060744. PMCID: PMC10139882. DOI: 10.1016/j.ebiom.2023.104560. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10139882/
li-2021-klebsiella-23butanediol - Li NN, Bai HL, Gao J, et al. High Alcohol-Producing Klebsiella pneumoniae Causes Fatty Liver Disease Through 2,3-Butanediol Fermentation Pathway In Vivo. Gut Microbes. 2021;13(1):1979883. PMID: 34632939. PMCID: PMC8510565. DOI: 10.1080/19490976.2021.1979883. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8510565/
edenberg-2007-adh-aldh-genetics - Edenberg HJ. The Genetics of Alcohol Metabolism: Role of Alcohol Dehydrogenase and Aldehyde Dehydrogenase Variants. Alcohol Research & Health. 2007;30(1):5-13. PMID: 17718394. PMCID: PMC3860432. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3860432/
spinucci-2006-pseudoobstruction - Spinucci G, Guidetti M, Lanzoni E, Pironi L. Endogenous Ethanol Production in a Patient with Chronic Intestinal Pseudo-Obstruction and Small Intestinal Bacterial Overgrowth. European Journal of Gastroenterology & Hepatology. 2006;18(7):799-802. PMID: 16772842. DOI: 10.1097/01.meg.0000223906.55245.61. URL: https://pubmed.ncbi.nlm.nih.gov/16772842/
jansson-nettelbladt-2006-sbs-child - Jansson-Nettelbladt E, Meurling S, Petrini B, Sjölin J. Endogenous Ethanol Fermentation in a Child with Short Bowel Syndrome. Acta Paediatrica. 2006;95(4):502-504. PMID: 16720504. DOI: 10.1080/08035250500469427. URL: https://pubmed.ncbi.nlm.nih.gov/16720504/
hafez-2017-endogenous-ethanol - Hafez EM, Hamad ME, Fouad M, Abdel-Lateff A. Auto-Brewery Syndrome: Ethanol Pseudo-Toxicity in Diabetic and Hepatic Patients. Human & Experimental Toxicology. 2017;36(5):445-450. PMID: 27492480. DOI: 10.1177/0960327116661400. URL: https://pubmed.ncbi.nlm.nih.gov/27492480/
kowlgi-2015-dlactic-acidosis - Kowlgi NG, Chhabra L. D-Lactic Acidosis: An Underrecognized Complication of Short Bowel Syndrome. Gastroenterology Research and Practice. 2015;2015:476215. PMID: 25977687. PMCID: PMC4421027. DOI: 10.1155/2015/476215. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4421027/
tamama-2024-bladder-gut-fermentation - Tamama K. Gut and Bladder Fermentation Syndromes: A Narrative Review. BMC Medicine. 2024;22:24. PMID: 38246992. PMCID: PMC10801939. DOI: 10.1186/s12916-023-03241-7. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10801939/
stamation-2025-alimentary-tract-ethanol - Stamation R. Endogenous Ethanol Production in the Human Alimentary Tract: A Literature Review. Journal of Gastroenterology and Hepatology. 2025;40(4):783-790. PMID: 39853762. DOI: 10.1111/jgh.16869. URL: https://pubmed.ncbi.nlm.nih.gov/39853762/
COVID19-abs-2024 - Auto-Brewery Syndrome After COVID-19 Infection. ACG Case Reports Journal. 2024;11(2):e01248. PMCID: PMC10852359. DOI: 10.14309/crj.0000000000001248. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10852359/
kruckenberg-2020-urinary-abs - Kruckenberg KM, DiMartini AF, Rymer JA, Pasculle AW, Tamama K. Urinary Auto-Brewery Syndrome: A Case Report. Annals of Internal Medicine. 2020;172(10):702-704. PMID: 32092761. DOI: 10.7326/L19-0661. URL: https://pubmed.ncbi.nlm.nih.gov/32092761/